Mr. Sandy Pratt reports

EMERALD ANNOUNCES CLOSING OF $24.4 MILLION BOUGHT DEAL

Emerald Health Therapeutics Inc. has closed its public offering announced on April 10 and April 11, 2017. Pursuant to the offering, the company has issued 13.17 million units at a price per unit of $1.85 for gross proceeds of $24,364,500. Eight Capital acted as underwriter for the offering.

The company also granted the underwriter an overallotment option to purchase up to an additional 1,975,500 units at the offering price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the offering. If this option is exercised in full, an additional $3,654,675 will be raised pursuant to the offering and the aggregate proceeds of the offering will be $28,019,175. Such overallotment option remains outstanding and has not been exercised as of the date of this news release.

Each unit consists of one common share of the company and one-half of one common share purchase warrant. Each warrant entitles the holder thereof to acquire one share at a price of $2.60 per share for a period of 24 months following the closing of the offering. In the event that the closing price of the company's shares on the TSX Venture Exchange, or such other principal Canadian stock exchange on which the shares are then listed, is greater than $3.50 per share for a period of 20 consecutive trading days, the company may accelerate the expiry date of the warrants by giving notice to the holders thereof and in such case the warrants will expire on the 30th day after such notice is given.

Emerald issued to the underwriter a total of 395,100 compensation options in connection with the offering. Each such compensation option entitles the holder to acquire a unit at a price of $1.85 per unit for a period of 24 months following the closing of the offering.

The company intends to use the net proceeds of the offering to accelerate facility expansion, to carry out research and development, and for working capital and general corporate purposes.

The units were offered by way of a base shelf prospectus and a shelf prospectus supplement filed in all of the provinces of Canada, except Quebec.

About Emerald Health Therapeutics Inc.

Emerald Health Therapeutics operates primarily through Emerald Health Botanicals Inc., a wholly owned subsidiary of the company and a licensed producer under the access to cannabis for medical purposes regulations. Botanicals is authorized to cultivate and sell both dried medical cannabis flowers and medical cannabis oils in Canada. Botanicals currently operates an indoor cultivation facility in Victoria, B.C., and plans to construct a much larger purpose-built hybrid greenhouse facility on 32 acres in Metro Vancouver.

We seek Safe Harbor.